5-HT3 receptor assay using transgenic mammal

Multicellular living organisms and unmodified parts thereof and – Method of using a transgenic nonhuman animal in an in vivo...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S069100, C435S320100, C435S325000, C435S455000, C800S008000, C800S009000, C800S014000, C800S018000, C800S021000

Reexamination Certificate

active

06630612

ABSTRACT:

BACKGROUND OF THE INVENTION
The invention relates to transgenic mammals characterized by 5-HT
3
receptor over-expression in the central nervous system (CNS). In particular, the invention relates to such transgenic mammals having a significantly reduced desire for alcohol as compared to mice of the corresponding non-transgenic line.
1. Field of the Invention
5-HT
3
receptors belong to a group of receptor subtypes for 5-hydroxytryptophan (serotonin). 5-HT
3
receptors are primarily located presynaptically, and are known to modulate the release of a number of neurotransmitters, including GABA, acetylcholine, and dopamine. The receptors are ion-channel-coupled receptors, the only known receptors of this type in the serotonin family.
It is not yet clear how neurotransmitters such as serotonin regulate neuronal cell function. However, 5-HT
3
receptors are believed to play a role in neurochemical reward pathways associated with the phenomena of drug abuse and other clinical conditions by modulating dopamine release in the mesolimbic pathway.
2. Discussion of Related Art
Many drugs of abuse, including alcohol, result in the release of dopamine in the nucleus accumbens of the brain, a region associated with motivation and reward. 5-HT
3
receptor antagonists have been shown to cause a dose-dependent decrease in alcohol-stimulated dopamine release in the nucleus accumbens (
Eur. J. Pharmacol.
187: 287-289, 1990;
Alcohol
9: 17-22), and it appears that certain 5-HT
3
agonists can stimulate dopamine release in the nucleus accumbens (
Brain Res.
513: 156-160, 1990). Nicotine and opiates such as morphine also release dopamine in the nucleus accumbens, and this release can be blocked by 5-HT
3
receptor antagonists (
Eur. J. Pharmacol.
164: 515-519, 1989).
Animal studies have demonstrated that 5-HT
3
receptor antagonists can decrease alcohol self-administration (
Alcohol
26: 107-110, 1991; and others). In human studies, 5-HT
3
receptor antagonists decreased pleasurable effects of alcohol and increased abstinence in mild alcoholics (
Psychopharmacol.
112: 142-144, 1993;
Alcohol Clin. Exp Res.
18: 879-855, 1994). Also, 5-HT
3
antagonists enhanced the subjective feeling of intoxication produced by ethanol in at least one study (
Biol. Psychiatry
40: 514-521, 1996).
5-HT
3
antagonists have been proposed for treatment of drug withdrawal syndromes, chemotherapy and drug-induced nausea and emesis, and as antimigraine, anxiolytic, and antipsychotic agents (reported in U.S. Pat. No. 5,057,519 to Suberg, et al.).
Studies of the 5-HT
3
receptor have, however, been hampered by the low level of their normal expression in the CNS. 5-HT
3
receptors are expressed throughout the forebrain in extremely low amounts. The highest amounts of 5-HT
3
receptors appear to be present in the cingulate cortex, entorhinal cortex, hippocampus, and amygdala; the last has also been associated with drug abuse, but 5-HT
3
receptors in this brain region have been less well characterized than those in the nucleus accumbens, where 5-HT
3
receptors are particularly scarce.
SUMMARY OF THE DISCLOSURE
The inventions comprise transgenic mammals carrying an exogenous 5-HT
3
transgene in their genome for over-expression in the CNS, particularly the forebrain. The inventions further comprise mammalian embryos carrying the 5-HT
3
transgene capable of developing into viable transgenic animals whose progeny carry the transgene after breeding forward by sexual reproduction. The inventions additionally include DNA constructs comprising selected promoter+intron+5-HT
3
cDNA or DNA segments cloned into plasmids for ultimate insertion into the genome of a mammal.
The transgenic mammals of the invention are characterized by a high density of functional 5-HT
3
receptors in the CNS of the mammals. They also exhibit a decreased desire for alcohol as compared to genetically similar non-transgenic mammals and decreased aggressiveness.


REFERENCES:
patent: 5057519 (1991-10-01), Suberg
patent: 5766879 (1998-06-01), Gerald et al.
patent: 6252131 (2001-06-01), Allan et al.
S. R. Engel et al, 5-HT3 receptor over-expression decreases ethanol self administration in transgenic mice, (1988) 140-243-248.*
Philip A. Wood, Phenotype Assessment: Are You Missing Something? vol 50, No. 1 Feb. 2000.*
Curt D. Sigmund, Viewpoint: Are Studies in Genetically Altered Mice Out of Control? Vasc. Biol. Jun. 2000; 20 (6): 1425-9.*
V. G. Pursel et al, Expression and Performance in transgenic pigs, J. Reprod. Fert. Suppl. 40 (1990), 235-245.*
Catherine A. Kappel et al, Regulating gene expression in transgenic animals, Biotechnology 1992, 3:548-553.*
R.J. Wall, “Transgenic Livestock: Progress and Prospects for the Future,”Theriogenology, vol. 45, pp 57-68 (1996).
K.M. Wozniak, et al., “Antagonism of 5-HT3Receptors Attenuates the Effects of Ethanol on Extracellular Dopamine,”European J of Pharmacology, vol. 187, pp 287-289 (1990).
K. Yoshimoto, et al., “Alcohol Stimulates the Release of Dopamine and Serotonin in the Nucleus Accumbens,”Alcohol, vol. 9, pp 17-22 (1991).
J.K. Belknap, et al., “Voluntary Consumption of Ethanol in 15 Inbred Mouse Strains,”Phychopharmacology, vol. 112, pp 503-510 (1993).
A.D. Campbell, et al., “Serotonin-3 Receptor and Ethanol-Stimulated Dopamine Release in the Nucleus Accumbens,”Pharm Biochem and Behavior, vol. 51, No. 4, pp 835-842 (1995).
E. Carboni, et al., “Differential Inhibitory Effects of a 5-HT3Antagonist on Drug-Induced Stimulation of Dopamine Release,”European J of Pharm. , vol. 164, pp 515-519 (1989).
B.A. Johnson, “Attenuation of Some Alcohol-Induced Mood Changes and the Desire to Drink by 5-HT3Receptor Blockade: a Preliminary Study in Healthy Male Volunteers,”Phychopharmacology, vol. 112, pp 142-144 (1993).
J.H. Holland, “Regulating Gene Expression in Transgenic Animals,”.
L.H. Jiang, et al., “The Effect of Intraventricular Administration of the 5-HT3Receptor Agonist 2-Methylserotonin on the Release of Dopamine in the Nucleus Accumbens: an in vivo Chronocoulometric Study,”Brain Research, vol. 513, pp 156-160 (1990).
A.V. Maricq, et al., “Primary Structure and Functional Expression of the 5-HT3Receptor, a Serotonin-Gated Ion Channel,”Science, vol. 254, pp 532-437 (Oct. 18, 1991).
R.M. Shift, et al., “Ondansetron Alters Human Alcohol Intoxication,”Biol. Psychiatry, vol. 40, pp 514-521 (1996).
Tsien, J.Z., et al., “Subregion- and Cell Type-Restricted Gene Knockout in Mouse Brain,”Cell, vol. 87, pp 1317-1326 (Dec. 27, 1996).
Uetz, P., et al., “Organisation of the Murine 5-HT3Receptor Gene and Assignment to Human Chromosome 11,”FEBS Letters, vol. 339, pp 302-305 (1994).
Wight, D.C., et al., “Transgenic Mice: A Decade of Progress in Technology and Research,”Mutation Research, vol. 307, pp 429-440 (1994).
Brinster, R.L., et al., “Introns Increase Transcriptional Efficiency in Transgenic Mice,”Proc. Natl. Acad. Sci USA, vol. 85, pp 836-840 (Feb. 1988).
Burgin, K.E., et al., “In Situ Hybridization Histochemistry of Ca2+/Calmodulin-Dependent Protein Kinase in Developing Rat Brain,”J. Neurosci., vol. 10, No. 6, pp 1788-1798 (Jun. 1990).
DiMaio, D., et al (Maniatis) “Bovine Papillomavirus Vector that Propagates as a Plasmic in Both Mouse and Baceterial Cells,”Proc. Natl. Acad. Sci. USA, vol. 79, pp 4030-4034 (Jul. 1982).
Mayford, M., et al., “Control of Memory Formation Through Regulated Expression of a CaMKII Transgene,”Science, vol. 274, pp 1678-1683 (Dec. 6, 1996).
Mayford, M., et al., “CaMKII Function in the Nervous System Explored from a Genetic Perspective,”Cold Spring Harbor Symposia on Quantitative Biology, vol. 62, pp 219-224 (1996).
Mayford, M., et al., “Memory and Behavior: A Second Generation of Genetically Modified Mice,”Current Biool., vol. 7, pp R580-R589 (1997).
Mayford, M., et al., “The 3′-untranslated Region of CaMKII&agr; is a Cis-Acting Signal for the Localization and Translation of mRNA in Dentrites,”Proc. Natl. Acad. Sci USA, vol. 93, pp 13250-13255 (Nov. 1996).
Rotenberg, A., et al., “Mice Expressing Activated CaMKII Lack Low Frequency LTP and Do not Form Stable Place

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

5-HT3 receptor assay using transgenic mammal does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 5-HT3 receptor assay using transgenic mammal, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-HT3 receptor assay using transgenic mammal will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3174946

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.